Pathfinders in Biopharma

Perspectives from the cutting edge of biotech and pharma.

The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.

Lead today. Define tomorrow.

Explore the Series

#Pathfinders

Ionis: Raising the Bar for ESG

In this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Beth Hougen, CFO of Ionis Pharma – a leading innovator in the development of antisense medicines and RNA-targeted therapeutics – to find out how the firm is embedding ESG into its vision, strategy and performance.

Listen NowRead Article

Listen Time 24mRead Time 3m

#Pathfinders

Biotech and Big Pharma: Blueprint for Successful Partnership

As biotech firms and large pharma companies find new synergies to bring new treatments to market together, RBC Capital Markets’ Noël Brown interviews pharma industry veteran Greg Wiederrecht – now RBC’s Biopharma Managing Director - on what it takes to ensure a strategic partnership not only survives but thrives.

Listen NowRead Article

Listen Time 23mRead Time 5m

Insights

Biotech Halftime Report: After a Bumpy Year, is Biotech Ready to Bounce Back?

There are encouraging signs that biotech is approaching a bottom after a rough start to 2021, but it’s difficult to call when the sector will bounce back.

Read Article

Read Time 4m

Insights

Game Changers: Disruptive Forces in Biotech

The biopharma sector continues to disrupt and be disrupted. Whether it’s products and technologies, legal developments or the knock-on effects of the coronavirus pandemic, there is a quiet revolution taking place right now that holds the potential to radically transform the world of healthcare. The paradigm shift in how we care for ourselves is already underway.

Read Article

Read Time 4m

#Pathfinders

Inside Track: Behind the Scenes of a Major Biotech SPAC

RBC Capital Markets’ Noël Brown, Head of US Biotech Investment Banking, goes behind the scenes of one of the biggest biotech SPAC deals of the year with Nuvation Bio Founder and CEO, Dr. David Hung and Omega Funds Partner and President of its Omega Alpha SPAC, Michelle Doig.

Listen NowRead Article

Listen Time 24mRead Time 4m

Insights

All eyes on gene/cell therapy and rare disease innovations

Every spring, RBC Capital Markets brings together key opinion leaders across major therapeutic areas in biotech for a series of Doctor Day sessions. This year, RBC’s Biotech Equity Research Analysts hosted experts with medical specialties from rare diseases to oncology to talk about future treatments, exciting innovations and life-changing advances. Many of these health issues have little in common, but there’s one area of innovation that could help treat them all – gene and cell therapies.

Read Article

Read Time 5m

Insights

Genetic Medicine Leads a Surge of Innovation in Biotech

According to RBC’s Senior Biotech Equity Analyst, Luca Issi, genetic medicine (the delivery of genetic material as a therapeutic) has attracted record-breaking capital in Biotech with ~$150b deployed across venture, IPOs, follow-ons and M&A since 2013. For context, that compares to the GDP of a top 50-60 country worldwide.

Read Article

Read Time 3m

#Pathfinders

What’s Material in ESG for Biopharma Firms?

In this episode of Pathfinders, Brian Abrahams, Co-Head of Biotechnology Equity Research at RBC Capital Markets speaks with the team of ESG leads at Gilead Sciences to understand the five key components driving the company’s ESG strategy, how this strategy has evolved and how it drives business impact.

Listen NowRead Article

Listen Time 18mRead Time 4m

Subscribe to Future Episodes of Pathfinders

Our podcast series explores the fast-moving world of Biopharma and what the road ahead looks like for companies and investors in the sector.

Subscribe Now

Recent Deals

Connect with our Bankers

About the Team

A Leading Partner for the Biopharma Industry

Our specialty expertise, combined with outstanding execution, has resulted in recurring transactions for biopharma clients as we partner with them through each stage of their development and growth.

 

More from RBC Capital Markets

Navigating the Changing Face of Healthcare

Navigating the Changing Face of Healthcare

Healthcare is in the midst of a revolution. From the challenges facing individual sectors to breakthrough innovations, gain the insights you need into the forces that are reshaping the industry.

Learn More
A Leader in Global Insights

A Leader in Global Insights

Access market and industry insights, commentary and analysis from our expert team to gain the perspective you need to make the most informed decisions.

Get More Insights

Stay Informed

Get the latest insights from RBC Capital Markets delivered to your inbox.